Smith & Nephew plc
EURO STOXX 600Last update: Mar 25, 2026 at 04:53
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Dividend Overview
Dividend Yield
2.40%
Annual Dividend
£0.29
Frequency
Semi-Annual
Payout Ratio
52.72%
FCF Payout Ratio
81.17%
Stock Price
£12.03
52-Week Range
£9.38 – £14.41
Dividend Health Score
SN.L's dividend appears safe and well-supported. Strengths include a 52.7% earnings payout ratio & 34.1% cfo payout ratio. Areas of concern: 81.2% fcf payout ratio & Volatile profit margin stability.
Based on 15 of 15 metrics
Payout & Coverage
SafeBalance Sheet
SafeProfitability
CautionDividend Track Record
SafeDividend History (2016–2025)
SN.L annual dividend per share and yield history
Earnings & Profitability
SN.L earnings per share and net profit margin
Key Dates
Next Ex-Dividend Date
March 26, 2026
Next Payment Date
—
Dividend Growth
3-Year Dividend CAGR
-2.91%
5-Year Dividend CAGR
-0.74%
10-Year Dividend CAGR
8.79%
3-Year Total Growth
-8.49%
5-Year Total Growth
-3.62%
10-Year Total Growth
132.19%
Income Calculator
Similar Dividend Stocks
Frequently Asked Questions
What is SN.L's current dividend yield?
When is SN.L's next dividend payment date?
How much does SN.L pay in dividends per year?
Has SN.L been increasing its dividend?
Is SN.L's dividend safe?
How is SN.L's Dividend Health Score calculated?
Want to understand how we rate dividend safety? Read our full methodology
Track SN.L Dividends with OnlyDividends
What will SN.L actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.
This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.
Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Health Score, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.
Market data provided by Twelve Data.